Skip to main content

Human IFN-alpha 2/IFNA2 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB9345

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
MAB9345-100
MAB9345-SP

Key Product Details

Species Reactivity

Human

Applications

Immunocytochemistry

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 967314

Product Specifications

Immunogen

Human embryonic kidney cell line HEK-293-derived transfected with human IFN-alpha 2/IFNA2
Met1-Glu188
Accession # P01563

Specificity

Detects human IFN-alpha 2/IFNA2 in ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) IFNE, rhIFNB, rhIFNG, or recombinant cotton rat IFNA is observed. In sandwich ELISAs, less than 8% cross-reactivity with rhIFNA-7, rhIFNA-8, and rhIFNA-10 is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for Human IFN-alpha 2/IFNA2 Antibody

IFN-a2/IFNA2 antibody in HeLa Human Cell Line by Immunocytochemistry (ICC).

IFN‑ alpha2/IFNA2 in HeLa Human Cell Line.

IFN-a2/IFNA2 was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line using Mouse Anti-Human IFN-a2/IFNA2 Monoclonal Antibody (Catalog # MAB9345) at 8 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Applications for Human IFN-alpha 2/IFNA2 Antibody

Application
Recommended Usage

Immunocytochemistry

8-25 µg/mL
Sample: Immersion fixed HeLa human cervical epithelial carcinoma cell line

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-alpha 2/IFNA2

Interferon-alpha 2 (IFNA2), also known as leukocyte interferon, is a type I interferon  produced by macrophages,  CD8 resting T cells, tonsillar NK cells, germinal center B cells, as well as epithelial cells, tumor cells and melanocytes. IFN alpha has at least nine different isoforms.

IFNA2 is a ligand for a cell surface receptor with two subunits, IFN-alpha R2 (ligand binding) and IFN-alpha R1 (ligand binding and signal transduction). IFNA2 has both antiviral and immunomodulatory activities on target cells.  Intranasal administration has been shown to reduce viral load in subjects with the common cold. While IFNA2 is a prognostic factor for hepatocellular carcinoma, Interferon alpha 2b, has been used to treat melanoma, renal cell carcinoma, chronic myelogenous leukemia and hepatitis C.

Long Name

Interferon alpha 2

Alternate Names

Ifa2, IFNA2, IFNA2a, IFNA2b, IFNA2c, IFNAA, IFNalpha 2

Entrez Gene IDs

3440 (Human); 15965 (Mouse); 298213 (Rat)

Gene Symbol

IFNA2

UniProt

Additional IFN-alpha 2/IFNA2 Products

Product Documents for Human IFN-alpha 2/IFNA2 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human IFN-alpha 2/IFNA2 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...